These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 22687754)

  • 1. Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines.
    Valdez BC; Nieto Y; Murray D; Li Y; Wang G; Champlin RE; Andersson BS
    Exp Hematol; 2012 Oct; 40(10):800-10. PubMed ID: 22687754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cladribine, gemcitabine, busulfan, and SAHA combination as a potential pretransplant conditioning regimen for lymphomas: A preclinical study.
    Ji J; Valdez BC; Li Y; Liu Y; Teo EC; Nieto Y; Champlin RE; Andersson BS
    Exp Hematol; 2016 Jun; 44(6):458-65. PubMed ID: 26976752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic cytotoxicity of the DNA alkylating agent busulfan, nucleoside analogs and suberoylanilide hydroxamic acid in lymphoma cell lines.
    Valdez BC; Murray D; Nieto Y; Li Y; Wang G; Champlin RE; Andersson BS
    Leuk Lymphoma; 2012 May; 53(5):973-81. PubMed ID: 22023523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic cytotoxicity of busulfan, melphalan, gemcitabine, panobinostat, and bortezomib in lymphoma cells.
    Teo EC; Valdez BC; Ji J; Li Y; Liu Y; Brammer JE; Hosing C; Nieto Y; Champlin RE; Andersson BS
    Leuk Lymphoma; 2016 Nov; 57(11):2644-52. PubMed ID: 26980288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B.
    Palii SS; Van Emburgh BO; Sankpal UT; Brown KD; Robertson KD
    Mol Cell Biol; 2008 Jan; 28(2):752-71. PubMed ID: 17991895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas.
    Nieto Y; Valdez BC; Thall PF; Ahmed S; Jones RB; Hosing C; Popat U; Shpall EJ; Qazilbash M; Gulbis A; Anderlini P; Alousi A; Shah N; Bashir Q; Liu Y; Oki Y; Hagemeister F; Fanale M; Dabaja B; Pinnix C; Champlin R; Andersson BS
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1914-20. PubMed ID: 26071868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest.
    Vijayaraghavalu S; Dermawan JK; Cheriyath V; Labhasetwar V
    Mol Pharm; 2013 Jan; 10(1):337-52. PubMed ID: 23215027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High DNA methyltransferase 3B expression mediates 5-aza-deoxycytidine hypersensitivity in testicular germ cell tumors.
    Beyrouthy MJ; Garner KM; Hever MP; Freemantle SJ; Eastman A; Dmitrovsky E; Spinella MJ
    Cancer Res; 2009 Dec; 69(24):9360-6. PubMed ID: 19951990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The histone deacetylase inhibitor SAHA sensitizes acute myeloid leukemia cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan.
    Song G; Valdez BC; Li Y; Dominguez JR; Corn P; Champlin RE; Andersson BS
    Leuk Lymphoma; 2014 Jul; 55(7):1625-34. PubMed ID: 24144307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Panobinostat and venetoclax enhance the cytotoxicity of gemcitabine, busulfan, and melphalan in multiple myeloma cells.
    Valdez BC; Li Y; Murray D; Liu Y; Nieto Y; Bashir Q; Qazilbash MH; Andersson BS
    Exp Hematol; 2020 Jan; 81():32-41. PubMed ID: 31954171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy.
    Chen MY; Liao WS; Lu Z; Bornmann WG; Hennessey V; Washington MN; Rosner GL; Yu Y; Ahmed AA; Bast RC
    Cancer; 2011 Oct; 117(19):4424-38. PubMed ID: 21491416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
    Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
    Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma.
    Nieto Y; Valdez BC; Thall PF; Jones RB; Wei W; Myers A; Hosing C; Ahmed S; Popat U; Shpall EJ; Qazilbash M; Gulbis A; Anderlini P; Shah N; Bashir Q; Alousi A; Oki Y; Fanale M; Dabaja B; Pinnix C; Champlin R; Andersson BS
    Cancer; 2016 Sep; 122(17):2680-8. PubMed ID: 27203405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodeling.
    Valdez BC; Li Y; Murray D; Champlin RE; Andersson BS
    Biochem Pharmacol; 2011 Jan; 81(2):222-32. PubMed ID: 20933509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine reactivates epigenetically silenced genes and functions as a DNA methyltransferase inhibitor.
    Gray SG; Baird AM; O'Kelly F; Nikolaidis G; Almgren M; Meunier A; Dockry E; Hollywood D; Ekström TJ; Perry AS; O'Byrne KJ
    Int J Mol Med; 2012 Dec; 30(6):1505-11. PubMed ID: 23007409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma.
    Venturelli S; Armeanu S; Pathil A; Hsieh CJ; Weiss TS; Vonthein R; Wehrmann M; Gregor M; Lauer UM; Bitzer M
    Cancer; 2007 May; 109(10):2132-41. PubMed ID: 17407132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical evaluation of antineoplastic activity of inhibitors of DNA methylation (5-aza-2'-deoxycytidine) and histone deacetylation (trichostatin A, depsipeptide) in combination against myeloid leukemic cells.
    Shaker S; Bernstein M; Momparler LF; Momparler RL
    Leuk Res; 2003 May; 27(5):437-44. PubMed ID: 12620295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-Aza-2'-deoxycytidine (decitabine) on human breast carcinoma cells.
    Hurtubise A; Momparler RL
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):618-25. PubMed ID: 16783580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic reactivation of estrogen receptor-α (ERα) by genistein enhances hormonal therapy sensitivity in ERα-negative breast cancer.
    Li Y; Meeran SM; Patel SN; Chen H; Hardy TM; Tollefsbol TO
    Mol Cancer; 2013 Feb; 12():9. PubMed ID: 23379261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the cytotoxicity of cladribine and clofarabine when combined with fludarabine and busulfan in AML cells: Enhancement of cytotoxicity with epigenetic modulators.
    Valdez BC; Li Y; Murray D; Ji J; Liu Y; Popat U; Champlin RE; Andersson BS
    Exp Hematol; 2015 Jun; 43(6):448-61.e2. PubMed ID: 25704054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.